$ARWR
ARROWHEAD PHARMACEUTICALS, INC.

2024 Q3 Form 10-Q Financial Statement

#000162828024036104 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $28.29M $26.16M
YoY Change 5.63% -1.98%
% of Gross Profit
Research & Development $128.9M $152.4M
YoY Change 37.43% 60.87%
% of Gross Profit
Depreciation & Amortization $5.025M $4.400M
YoY Change 29.08% 51.72%
% of Gross Profit
Operating Expenses $162.2M $176.1M
YoY Change 30.36% 48.61%
Operating Profit -$176.1M
YoY Change 71.51%
Interest Expense -$7.477M $1.404M
YoY Change 442.99% -72.78%
% of Operating Profit
Other Income/Expense, Net -$3.118M $2.164M
YoY Change -534.87% -418.24%
Pretax Income -$172.8M -$174.0M
YoY Change 58.54% 68.28%
Income Tax $546.0K $0.00
% Of Pretax Income
Net Earnings -$170.5M -$170.8M
YoY Change 55.49% 65.91%
Net Earnings / Revenue
Basic Earnings Per Share -$1.38
Diluted Earnings Per Share -$1.37 -$1.38
COMMON SHARES
Basic Shares Outstanding 124.3M shares 124.2M shares
Diluted Shares Outstanding 124.2M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $681.0M $436.7M
YoY Change 68.73% -3.33%
Cash & Equivalents $102.7M $69.40M
Short-Term Investments $578.3M $367.3M
Other Short-Term Assets $4.973M $4.184M
YoY Change -29.78% -41.58%
Inventory
Prepaid Expenses $9.537M $9.207M
Receivables
Other Receivables
Total Short-Term Assets $695.5M $450.1M
YoY Change 65.78% -4.28%
LONG-TERM ASSETS
Property, Plant & Equipment $386.0M $375.9M
YoY Change 32.99% 62.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.482M $4.460M
YoY Change 2034.29% 2023.81%
Total Long-Term Assets $444.3M $433.7M
YoY Change 28.41% 33.16%
TOTAL ASSETS
Total Short-Term Assets $695.5M $450.1M
Total Long-Term Assets $444.3M $433.7M
Total Assets $1.140B $883.8M
YoY Change 48.89% 11.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.39M $26.55M
YoY Change -68.25% 237.19%
Accrued Expenses $63.02M $47.90M
YoY Change 58.48% 25.42%
Deferred Revenue $0.00 $0.00
YoY Change -100.0% -100.0%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $103.2M $96.71M
YoY Change -2.17% 37.72%
LONG-TERM LIABILITIES
Long-Term Debt $393.2M $0.00
YoY Change
Other Long-Term Liabilities $452.4M $448.1M
YoY Change 21.31% 66876.23%
Total Long-Term Liabilities $845.6M $448.1M
YoY Change 126.73% 30.39%
TOTAL LIABILITIES
Total Short-Term Liabilities $103.2M $96.71M
Total Long-Term Liabilities $845.6M $448.1M
Total Liabilities $948.7M $544.8M
YoY Change 98.32% 31.63%
SHAREHOLDERS EQUITY
Retained Earnings -$1.626B -$1.455B
YoY Change 58.43% 58.78%
Common Stock $1.806B $1.787B
YoY Change 38.88% 39.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $185.4M $330.5M
YoY Change
Total Liabilities & Shareholders Equity $1.140B $883.8M
YoY Change 48.89% 11.05%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$170.5M -$170.8M
YoY Change 55.49% 65.91%
Depreciation, Depletion And Amortization $5.025M $4.400M
YoY Change 29.08% 51.72%
Cash From Operating Activities -$137.2M -$115.4M
YoY Change 442.57% 438.18%
INVESTING ACTIVITIES
Capital Expenditures $24.29M $14.45M
YoY Change -62.01% -69.0%
Acquisitions
YoY Change
Other Investing Activities -$198.6M $21.40M
YoY Change -310.46% -41.69%
Cash From Investing Activities -$222.9M $6.949M
YoY Change -829.82% -170.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 389.1M 50.39M
YoY Change 254206.54% 2691.52%
NET CHANGE
Cash From Operating Activities -137.2M -115.4M
Cash From Investing Activities -222.9M 6.949M
Cash From Financing Activities 389.1M 50.39M
Net Change In Cash 28.95M -58.08M
YoY Change 435.32% 96.58%
FREE CASH FLOW
Cash From Operating Activities -$137.2M -$115.4M
Capital Expenditures $24.29M $14.45M
Free Cash Flow -$161.5M -$129.9M
YoY Change 81.0% 90.84%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Transition Report
DocumentTransitionReport
false
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-139000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-275000 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-434114000 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-98535000 usd
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Amendment Flag
AmendmentFlag
false
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity Registrant Name
EntityRegistrantName
ARROWHEAD PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-0408024
dei Entity Address Address Line1
EntityAddressAddressLine1
177 E. Colorado Blvd
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 700
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
124315274 shares
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
69399000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
110891000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
367272000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
292735000 usd
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
9207000 usd
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
8813000 usd
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
4184000 usd
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
4033000 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
450062000 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
416472000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
375911000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
290262000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
8987000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
10262000 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
44339000 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
45297000 usd
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4460000 usd
CY2024Q2 us-gaap Assets
Assets
883759000 usd
CY2023Q3 us-gaap Assets
Assets
765552000 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
35866000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
47899000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
39763000 usd
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
15795000 usd
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
17963000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6053000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
10563000 usd
CY2024Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0 usd
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
866000 usd
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
417000 usd
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
435000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
104608000 usd
CY2024Q2 arwr Royalties Liability Noncurrent
RoyaltiesLiabilityNoncurrent
336031000 usd
CY2023Q3 arwr Royalties Liability Noncurrent
RoyaltiesLiabilityNoncurrent
268326000 usd
CY2024Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
448071000 usd
CY2023Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
372934000 usd
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
290000000 shares
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
290000000 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
124227000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
124227000 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
217000 usd
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
200000 usd
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1786304000 usd
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1300395000 usd
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-987000 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3222000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1454987000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1026030000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
330547000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
271343000 usd
CY2024Q2 us-gaap Minority Interest
MinorityInterest
8427000 usd
CY2023Q3 us-gaap Minority Interest
MinorityInterest
15819000 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
338974000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
287162000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
883759000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15825000 usd
dei Entity Address City Or Town
EntityAddressCityOrTown
Pasadena
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
91105
dei City Area Code
CityAreaCode
626
dei Local Phone Number
LocalPhoneNumber
304-3400
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
ARWR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3259000 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
26550000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
105456000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
112040000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
765552000 usd
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3551000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
224638000 usd
CY2024Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
152431000 usd
CY2023Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
94757000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
370044000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
253333000 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23710000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23771000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
72384000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
67977000 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
176141000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
118528000 usd
us-gaap Operating Expenses
OperatingExpenses
442428000 usd
us-gaap Operating Expenses
OperatingExpenses
321310000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-176141000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-102703000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-438877000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-96672000 usd
CY2024Q2 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
6498000 usd
CY2023Q2 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
4172000 usd
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
11414000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
306000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1370000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
821000 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2164000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-680000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-785000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-829000 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-173977000 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-103383000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-439662000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-97501000 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
742000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3313000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
759000 usd
CY2024Q2 us-gaap Profit Loss
ProfitLoss
-173977000 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-104125000 usd
us-gaap Profit Loss
ProfitLoss
-436349000 usd
us-gaap Profit Loss
ProfitLoss
-98260000 usd
CY2024Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-3184000 usd
CY2023Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1179000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-7392000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2664000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-170793000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-102946000 usd
us-gaap Net Income Loss
NetIncomeLoss
-428957000 usd
us-gaap Net Income Loss
NetIncomeLoss
-95596000 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.38
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.96
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.63
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.90
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.96
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.63
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.90
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
124199000 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
107004000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
118260000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
106597000 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
124199000 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
107004000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
118260000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
106597000 shares
CY2024Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
249000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
2374000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-141000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-79000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-104204000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
287162000 usd
CY2023Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19694000 usd
CY2023Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
267000 usd
CY2023Q4 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
58000 usd
CY2023Q4 us-gaap Profit Loss
ProfitLoss
-135376000 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
173714000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17750000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1512000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
429265000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-56000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
216000 usd
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-126996000 usd
dei Entity Central Index Key
EntityCentralIndexKey
0000879407
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
96714000 usd
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
107312000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
107312000 shares
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
15550000 usd
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
5094000 usd
CY2023Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
5158000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
17705000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
13064000 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
760000 usd
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.38
CY2024Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-173869000 usd
CY2023Q4 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1909000 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
495405000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17050000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
388000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-141000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
249000 usd
CY2024Q2 us-gaap Profit Loss
ProfitLoss
-173977000 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
338974000 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
418339000 usd
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19390000 usd
CY2022Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
576000 usd
CY2022Q4 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 usd
CY2022Q4 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-122000 usd
CY2022Q4 us-gaap Profit Loss
ProfitLoss
-41811000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
396372000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20612000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
520000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-74000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
47676000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
465106000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19947000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1136000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-79000 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-104125000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
381985000 usd
us-gaap Profit Loss
ProfitLoss
-436349000 usd
us-gaap Profit Loss
ProfitLoss
-98260000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
54494000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
59949000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
13570000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
8634000 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
1030000 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
80000 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0 usd
arwr Non Cash Interest Expense Liability Related To Sale Of Future Royalties
NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties
17705000 usd
arwr Non Cash Interest Expense Liability Related To Sale Of Future Royalties
NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties
13064000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-164000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1746000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-27913000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2785000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5001000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
13086000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-32082000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-866000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-113144000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
3880000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
1827000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-325635000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-127964000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
117180000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
112830000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
428611000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
233984000 usd
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
348642000 usd
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
220150000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-197149000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-126664000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2166000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2232000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
429265000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
arwr Proceeds From Sale Of Future Royalties
ProceedsFromSaleOfFutureRoyalties
50000000 usd
arwr Proceeds From Sale Of Future Royalties
ProceedsFromSaleOfFutureRoyalties
250000000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
481431000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
252232000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-41353000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2396000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-139000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-275000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
110891000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
108005000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
69399000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
105334000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-3062000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
6909000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
15624000 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
69400000 usd
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
2200000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
367300000 usd
arwr Increase Decrease In Cash And Investments
IncreaseDecreaseInCashAndInvestments
33000000.0 usd
CY2024Q2 arwr Development Regulatory And Sales Milestones Payments
DevelopmentRegulatoryAndSalesMilestonesPayments
2700000000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3300000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
800000 usd
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15825000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3551000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
224638000 usd
CY2024Q2 us-gaap Accounts Receivable Net
AccountsReceivableNet
0 usd
CY2023Q3 us-gaap Accounts Receivable Net
AccountsReceivableNet
0 usd
CY2024Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0 usd
CY2023Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
866000 usd
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
429814000 usd
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
332213000 usd
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
53903000 usd
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
41951000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
375911000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
290262000 usd
CY2024Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4400000 usd
CY2023Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2900000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
12300000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7400000 usd
CY2024Q2 arwr Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
17911000 usd
CY2023Q3 arwr Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
16125000 usd
CY2024Q2 arwr Accrued Research And Development Co Development Expense Current
AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent
21280000 usd
CY2023Q3 arwr Accrued Research And Development Co Development Expense Current
AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent
5895000 usd
CY2024Q2 arwr Accrued Capital Expenditure Current
AccruedCapitalExpenditureCurrent
6909000 usd
CY2023Q3 arwr Accrued Capital Expenditure Current
AccruedCapitalExpenditureCurrent
14044000 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1799000 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3699000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
47899000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
39763000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
367862000 usd
CY2024Q2 arwr Debt Securities Available For Sale Accumulated Gross Unrealized Gain Current
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent
8000 usd
CY2024Q2 arwr Debt Securities Available For Sale Accumulated Gross Unrealized Loss Current
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent
598000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
367272000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
295699000 usd
CY2023Q3 arwr Debt Securities Available For Sale Accumulated Gross Unrealized Gain Current
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent
3000 usd
CY2023Q3 arwr Debt Securities Available For Sale Accumulated Gross Unrealized Loss Current
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent
2967000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
292735000 usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
400000 usd
CY2024Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
400000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1300000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1300000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
425000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1700000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1700000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1700000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1700000 usd
CY2024Q2 arwr Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
1762000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
8987000 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
290000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
124227000 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
124227000 shares
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
290000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
107312000 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
107312000 shares
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
44339000 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
45297000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6053000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
10563000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
112040000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
104608000 usd
CY2024Q2 us-gaap Lease Cost
LeaseCost
4365000 usd
CY2023Q2 us-gaap Lease Cost
LeaseCost
4089000 usd
us-gaap Lease Cost
LeaseCost
12513000 usd
us-gaap Lease Cost
LeaseCost
9904000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
0 usd
CY2023Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
600000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
1200000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
3793000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
15356000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
15696000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
14869000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
13511000 usd
CY2024Q2 arwr Lessee Operating Lease Liability Payments Due Year Five And After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive
128356000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
191581000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
73488000 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
118093000 usd
CY2024Q2 arwr Operating Lease Cash Received For Amounts Included In Measurement Of Lease Liabilities
OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities
0 usd
CY2023Q2 arwr Operating Lease Cash Received For Amounts Included In Measurement Of Lease Liabilities
OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities
5414000 usd
arwr Operating Lease Cash Received For Amounts Included In Measurement Of Lease Liabilities
OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities
3099000 usd
arwr Operating Lease Cash Received For Amounts Included In Measurement Of Lease Liabilities
OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities
23343000 usd
CY2024Q2 arwr Right Of Use Asset Adjustment In Exchange For Operating Lease Liability
RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability
0 usd
CY2023Q2 arwr Right Of Use Asset Adjustment In Exchange For Operating Lease Liability
RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability
3519000 usd
arwr Right Of Use Asset Adjustment In Exchange For Operating Lease Liability
RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability
-64000 usd
arwr Right Of Use Asset Adjustment In Exchange For Operating Lease Liability
RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability
-19063000 usd
CY2024Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
3204000 usd
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
1885000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
7221000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
4081000 usd
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P12Y9M18D
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P13Y4M24D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.080
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.080
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4565727 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2012497 shares
CY2024Q2 arwr Share Based Compensation Arrangement By Share Based Payment Award Options And Equity Instruments Other Than Options Outstanding
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding
7042421 shares
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14711000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19947000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
48984000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
59949000 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2263477 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
22.68
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
53582 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
36.62
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
197398 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
10.98
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2012497 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
23.22
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y9M18D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
22486304 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2001968 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
23.05
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y9M18D
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
22486304 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0369
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.864
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
24.80
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q3 arwr Royalties Liability Noncurrent
RoyaltiesLiabilityNoncurrent
268326000 usd
arwr Milestone Payment Received Liability Related To Sale Of Future Royalties
MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties
50000000 usd
arwr Non Cash Interest Expense Liability Related To Sale Of Future Royalties
NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties
17705000 usd
CY2024Q2 arwr Royalties Liability Noncurrent
RoyaltiesLiabilityNoncurrent
336031000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-170793000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-102946000 usd
us-gaap Net Income Loss
NetIncomeLoss
-428957000 usd
us-gaap Net Income Loss
NetIncomeLoss
-95596000 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
124199000 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
107004000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
118260000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
106597000 shares
CY2024Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2023Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
124199000 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
107004000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
118260000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
106597000 shares
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.38
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.96
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.63
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.90
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.38
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.96
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.63
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.90
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4729000 shares
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3467000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4771000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4024000 shares
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
arwr-20240630_pre.xml Edgar Link unprocessable
0001628280-24-036104-index-headers.html Edgar Link pending
0001628280-24-036104-index.html Edgar Link pending
0001628280-24-036104.txt Edgar Link pending
0001628280-24-036104-xbrl.zip Edgar Link pending
arwr-20240630.htm Edgar Link pending
arwr-20240630.xsd Edgar Link pending
arwr-2024630xex311.htm Edgar Link pending
arwr-2024630xex311001.jpg Edgar Link pending
arwr-2024630xex312.htm Edgar Link pending
arwr-2024630xex312001.jpg Edgar Link pending
arwr-2024630xex321.htm Edgar Link pending
arwr-2024630xex321001.jpg Edgar Link pending
arwr-2024630xex322.htm Edgar Link pending
arwr-2024630xex322001.jpg Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
arwr-20240630_def.xml Edgar Link unprocessable
arwr-20240630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
arwr-20240630_htm.xml Edgar Link completed
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
arwr-20240630_cal.xml Edgar Link unprocessable